NCT01178268View on ClinicalTrials.gov

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

PHASE4CompletedINTERVENTIONAL
Enrollment

546

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

September 30, 2014

Conditions
Coronary OcclusionThrombosis (Stent Thrombosis)Vascular DiseaseMyocardial IschemiaCoronary Artery StenosisCoronary DiseaseCoronary Artery DiseaseCoronary Restenosis
Interventions
DEVICE

XIENCE V EECSS

Patients who will receive this stent.

DEVICE

CYPHER SELECT PLUS SECSS

Patients who will receive this stent.

Trial Locations (2)

100037

Fu Wai Hospital, Beijing

200122

Authorized Representative in China Guidant International Trading (Shanghai) Co., Ltd., Shanghai

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY